Stockscreener 앱 받기
79.11
5.15%
3.93
전일 마감가:
$75.18
열려 있는:
$75.37
하루 거래량:
957.60K
Relative Volume:
0.96
시가총액:
$8.33B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
62.79
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
+6.35%
1개월 성능:
+10.16%
6개월 성능:
+39.91%
1년 성능:
+87.01%
1일 변동 폭
$74.89
$79.32
1주일 범위
$69.03
$79.32
52주 변동 폭
$40.62
$117.33
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
CORT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
79.05 | 7.92B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
386.89 | 99.26B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.08 | 62.06B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.64 | 59.21B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
730.05 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
342.09 | 36.57B | 3.81B | -644.79M | -669.77M | -6.24 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
Published on: 2025-09-18 11:43:17 - خودرو بانک
Livforsakringsbolaget Skandia Omsesidigt Has $1.44 Million Stake in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Incorporated $CORT Stock Holdings Increased by Voya Investment Management LLC - MarketBeat
Aug PostEarnings: Should I average down on CNOB stockEarnings Trend Report & Real-Time Chart Breakout Alerts - خودرو بانک
Gap Down: Is Topgolf Callaway Brands Corp. stock a good pick for beginners2025 Technical Patterns & AI Forecasted Entry and Exit Points - خودرو بانک
13,400 Shares in Corcept Therapeutics Incorporated $CORT Bought by Strs Ohio - MarketBeat
Alliancebernstein L.P. Lowers Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Incorporated $CORT Shares Bought by Jones Financial Companies Lllp - MarketBeat
Support Test: What is the next catalyst for QTRX2025 Market Outlook & Free Technical Pattern Based Buy Signals - خودرو بانک
Iron Gate Global Advisors LLC Buys Shares of 3,500 Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics Incorporated $CORT Stock Holdings Lifted by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - MarketBeat
Market Outlook: What is the next catalyst for FIZZMarket Performance Report & Consistent Growth Equity Picks - خودرو بانک
Corcept’s (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint - MSN
Buyback Watch: Can Corcept Therapeutics Incorporated weather a recession2025 Short Interest & Weekly Breakout Stock Alerts - خودرو بانک
Corcept Therapeutics Incorporated $CORT Stake Lowered by Parallel Advisors LLC - MarketBeat
United Services Automobile Association Acquires Shares of 6,069 Corcept Therapeutics Incorporated $CORT - MarketBeat
Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Corcept (CORT): Buy, Sell, or Hold Post Q2 Earnings? - FinancialContent
Intech Investment Management LLC Purchases 14,628 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Can't Escape Teva's Mifepristone Antitrust Suit - Law360
Corcept Fails to Escape Antitrust Claims in Drug Kickback Case - Bloomberg Law News
Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder - Reuters
Empowered Funds LLC Purchases 81,297 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Corcept Therapeutics (NASDAQ:CORT) Price Target Raised to $140.00 at Canaccord Genuity Group - MarketBeat
Bayforest Capital Ltd Has $811,000 Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Acadian Asset Management LLC Boosts Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Coppell Advisory Solutions LLC Buys 14,590 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
AQR Capital Management LLC Sells 23,561 Shares of Corcept Therapeutics Incorporated $CORT - MarketBeat
Scientech Research LLC Has $1.62 Million Stock Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Price Target at $134.50 - MarketBeat
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer - sharewise.com
FDA Accepts NDA for Relacorilant in Platinum-Resistant Ovarian Cancer - Targeted Oncology
Central serous chorioretinopathy Pipeline Analysis & Clinical - openPR.com
Central serous chorioretinopathy Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Targeted Therapy Technologies, Corcept Therapeutics, Bayer, and others - Barchart.com
Jacobs Levy Equity Management Inc. Decreases Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
FDA accepts Corcept’s new drug application for ovarian cancer treatment - Investing.com
Corcept's ovarian cancer treatment under FDA review (CORT) - Seeking Alpha
Corcept Therapeutics Says FDA Accepts NDA on Relacorilant for Treating Ovarian Cancer - MarketScreener
Fda reviews Corcept's nda for relacorilant in drug-resistant ovarian cancer - MarketScreener
FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
Checkpoint Capital L.P. Acquires Shares of 5,000 Corcept Therapeutics Incorporated $CORT - MarketBeat
Published on: 2025-09-08 19:18:57 - beatles.ru
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
코르셉트 테라퓨틱스 주식 (CORT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | Director |
Sep 10 '25 |
Sale |
72.45 |
2,200 |
159,390 |
0 |
0.07%
1.39%
자본화:
|
볼륨(24시간):